eli lilly ceo on how covid-19 antibody drug helped drive q4 earnings
Published 3 years ago • 1.2K plays • Length 4:39Download video MP4
Download video MP3
Similar videos
-
6:05
eli lilly ceo david ricks on q2 results: seeing unbelievable demand for zepbound and mounjaro
-
1:41
eli lilly ceo explains supply chain of covid-19 antibody drug
-
9:22
eli lilly ceo discusses its coronavirus antibody drug and the latest on its breast cancer treatment
-
3:14
eli lilly ceo on raising $1b for antibiotic research: goal is to have two to four new antibiotics
-
4:37
eli lilly ceo: covid-19 antibody treatment will help reduce hospitalizations
-
2:13
eli lilly ceo on covid antibody treatment's effectiveness against mutations
-
1:44
eli lilly confirms it has paused one of its covid-19 antibody tests
-
3:48
eli lilly’s chief scientific officer on covid antibody drug results
-
5:50
the labor market is slowing slightly but healthy overall, says evercore's roger altman
-
6:51
palantir co-founder joe lonsdale: i'm for holding big tech accountable, not radical regulators
-
4:03
weekly jobless claims fall to 233,000, less than expected, in a positive sign for labor market
-
3:32
eli lilly ceo david ricks on the end of antibody study in hospitalized patients
-
4:12
eli lilly ceo david ricks explains q1 earnings miss, lowered forecast
-
2:47
eli lilly hopes to start testing coronavirus cure 'this summer': ceo
-
1:15
eli lilly starts late-stage trial for covid-19 antibody drug in nursing homes
-
4:21
eli lilly cfo on q2 earnings and coronavirus treatment
-
2:41
eli lilly reports positive phase 3 trial results for covid antibody drug
-
8:21
eli lilly ceo talks partnering with abcellera biologics to co-develop a coronavirus cure
-
5:19
watch cnbc's interview with eli lilly's chief scientific officer on the new covid-19 antibody drug
-
1:54
coronavirus: eli lilly launches first human trial of a new type of treatment
-
3:13
eli lilly ceo: we see a path to an alzheimer's disease-modifying drug
-
1:51
lilly drug cuts risk of contracting covid-19 by 80%: study